Clinical trial · Observational
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2
NCT00398749CI-TRIAL-00008424completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to evaluate the safety and efficacy (% response) of epoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epoetin alfa | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Epoetin alfa
- description
- Epoetin alfa 40 000 IU once weekly variable treatment length
- interventionNames
- Drug: Epoetin alfa
Primary outcomes (1)
- measure
- The assessment of effectiveness based on: epoetin alfa treatment schedule (dose and timing), hemoglobin effect, response to treatment (independent of blood transfusion), mean time to response, # of blood transfusions given, and iron supplementation
- timeFrame
- 4 weeks, 8 weeks and end of treatment
Secondary outcomes (1)
- measure
- Incidence of adverse events
- timeFrame
- from start epoetin treatment to end of study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of solid tumors, multiple myeloma (Kahlers' disease), non-Hodgkin lymphoma or Hodgkins' disease * Patients must already be receiving chemotherapy or start their first cycle within a week of enrollment * Patients must receive epoetin alfa treatment (expected treatment duration is at least 4 weeks) Exclusion Criteria: * Patients who cannot read the Dutch language and/or do not understand the Dutch Informed Consent Form and patients participating in either of our observational studies, EVALUATE or COMPARE
References
Publications (0)
Data not yet available
No reference posted for this study.